Dexamethasone intravitreal implant (OZURDEX®) for macular edema secondary to noninfectious uveitis: a review of the literature-Reference-Cited by-同舟云学术

Dexamethasone intravitreal implant (OZURDEX®) for macular edema secondary to noninfectious uveitis: a review of the literature

Published:2019-06-01 Issue:6 Volume:10 Page:343-351
ISSN:2041-5990
Container-title:Therapeutic Delivery
language:en
Short-container-title:Therapeutic Delivery

Author:

Massa Horace¹,Georgoudis Panagiotis²,Panos Georgios D²^ORCID

Affiliation:

1. Department of Ophthalmology, Geneva University Hospitals & Faculty of Medicine, University of Geneva, Geneva, CH-1205, Switzerland

2. Eye Treatment Centre, Whipps Cross University Hospital, Barts Health NHS Trust, London, E11 1NR, UK

Abstract

Macular edema (ME) is the leading cause of visual loss in uveitis and may persist long after ocular inflammation has been resolved. Local steroids are the first line treatment for uveitis and uveitic ME. Dexamethasone intravitreal implant (OZURDEX®; Allergan, Inc., CA, USA) has been used to treat diabetic ME and ME secondary to retinal vein occlusion. Recent studies have also demonstrated that Ozurdex may be effective treatment for patients with persistent uveitic ME. In this review, we present the results of the real word studies concerning the efficacy and safety of Ozurdex for the treatment of uveitic ME.

Publisher

Future Science Ltd

Subject

Pharmaceutical Science

Link

https://www.future-science.com/doi/pdf/10.4155/tde-2019-0024

Reference68 articles.

1. Epidemiology of Uveitis

2. Incidence and prevalence of uveitis in Northern California The Northern California Epidemiology of Uveitis Study

3. International Uveitis Study Group (IUSG) Clinical Classification of Uveitis

4. Impact of Macular Edema on Visual Acuity in Uveitis

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of a dexamethasone implant to treat macular edema following pars plana vitrectomy and removal of the primary epiretinal membrane;International Ophthalmology;2024-08-05

2. Incisional choroidal surgery;Survey of Ophthalmology;2024-08

3. Improving corneal permeability of dexamethasone using penetration enhancing agents: First step towards achieving topical drug delivery to the retina;International Journal of Pharmaceutics;2024-07

4. Uveitis in the Pediatric Population and Therapeutic Management: A Current Literature Review;Children;2024-06-25

5. Optical coherence tomography biomarkers as outcome predictors to guide dexamethasone implant use in patients with iERM: a randomized controlled trial;BMC Ophthalmology;2024-04-25